☆ 4.3 Article

Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation?

Chanu Rhee et al.

Summary: SARS-CoV-2 is most contagious around symptom onset, with infectivity rapidly decreasing to near-zero afterwards; mild-moderately ill patients can safely discontinue isolation after about 10 days, while severely-critically ill and immunocompromised patients may need 15 days. The longest duration associated with replication-competent virus is 20 days.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Clinical Neurology

Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis

Amber Salter et al.

Summary: This study examined outcomes and risk factors associated with COVID-19 clinical severity in a large, diverse cohort of North American patients with multiple sclerosis. The study found that ambulatory disability, older age, male sex, Black race, cardiovascular comorbidities, and recent corticosteroid use were associated with increased odds of worse clinical severity in MS patients with COVID-19. Knowledge of these risk factors may help improve the treatment and monitoring of these patients.

JAMA NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France

Maria Pia Sormani et al.

Summary: This study evaluated the impact of disease-modifying therapies on Covid-19 severity in patients with multiple sclerosis through a pooled-analysis of two large cohorts. The results showed that anti-CD20 therapies were significantly associated with severe Covid-19, while interferon indicated a decreased risk.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy